The nociceptin receptor (NOP), also known as the nociceptin/orphanin FQ (N/OFQ) receptor or kappa-type 3 opioid receptor, is a protein that in humans is encoded by the OPRL1 (opioid receptor-like 1) gene. The nociceptin receptor is a member of the opioid subfamily of G protein-coupled receptors whose natural ligand is the 17 amino acid neuropeptide known as nociceptin (N/OFQ). This receptor is involved in the regulation of numerous brain activities, particularly instinctive and emotional behaviors.
Although NOP shares high sequence identity (~60%) with the ‘classical’ opioid receptors μ-OR (MOR), κ-OR (KOR), and δ-OR (DOR), it possesses little or no affinity for opioid peptides or morphine-like compounds. Likewise, classical opioid receptors possess little affinity towards NOP’s endogenous ligand nociceptin, which is structurally related to dynorphin A.
Several commonly used opioid drugs including etorphine and buprenorphine have been demonstrated to bind to nociceptin receptors, but this binding is relatively insignificant compared to their activity at other opioid receptors in the acute setting (however the non-analgesic NOPr antagonist SB-612,111 was demonstrated to potentiate the therapeutic benefits of morphine). Chronic administration of nociceptin receptor agonists results in an attentuation of the analgesic and anti-allodynic effects of opiates; this mechanism inhibits the action of endogenous opioids as well, resulting in an increase in pain severity, depression, and both physical and psychological opiate dependence following chronic NOPr agonist administration. Administration of the NOPr antagonist SB-612,111 has been shown to inhibit this process. More recently a range of selective ligands for NOP have been developed, which show little or no affinity to other opioid receptors and so allow NOP-mediated responses to be studied in isolation.
^Zaratin, PF; Petrone, G; Sbacchi, M; Garnier, M; Fossati, C; Petrillo, P; Ronzoni, S; Giardina, GA; Scheideler, MA (2004). "Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (−)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-ylmethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)". The Journal of Pharmacology and Experimental Therapeutics308 (2): 454–61. doi:10.1124/jpet.103.055848. PMID14593080.
^Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K. Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent. Journal of Pharmacological Sciences. 2008 Mar;106(3):361-8. PMID 18319566
^Scoto GM, Aricò G, Ronsisvalle S, Parenti C (Jul 2007). "Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia". Peptides28 (7): 1441–6. doi:10.1016/j.peptides.2007.05.013. PMID17628212.
^Redrobe JP, Calo' G, Regoli D, Quirion R (Feb 2002). "Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test". Naunyn-Schmiedeberg's Archives of Pharmacology365 (2): 164–7. doi:10.1007/s00210-001-0511-0. PMID11819035.
New DC, Wong YH (2003). "The ORL1 receptor: molecular pharmacology and signalling mechanisms". Neuro-Signals11 (4): 197–212. doi:10.1159/000065432. PMID12393946.
Zaveri N (Jun 2003). "Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents". Life Sciences73 (6): 663–78. doi:10.1016/S0024-3205(03)00387-4. PMID12801588.
Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH (Sep 1995). "Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines". Brain Research. Molecular Brain Research32 (2): 342–7. doi:10.1016/0169-328X(95)00096-B. PMID7500847.
Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B (Oct 1995). "Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor". Nature377 (6549): 532–5. doi:10.1038/377532a0. PMID7566152.
Yung LY, Joshi SA, Chan RY, Chan JS, Pei G, Wong YH (Jan 1999). "GalphaL1 (Galpha14) couples the opioid receptor-like1 receptor to stimulation of phospholipase C". The Journal of Pharmacology and Experimental Therapeutics288 (1): 232–8. PMID9862775.
Feild JA, Foley JJ, Testa TT, Nuthulaganti P, Ellis C, Sarau HM, Ames RS (Oct 1999). "Cloning and characterization of a rabbit ortholog of human Galpha16 and mouse G(alpha)15". FEBS Letters460 (1): 53–6. doi:10.1016/S0014-5793(99)01317-4. PMID10571060.
Mouledous L, Topham CM, Moisand C, Mollereau C, Meunier JC (Mar 2000). "Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain". Molecular Pharmacology57 (3): 495–502. PMID10692489.
Yung LY, Tsim KW, Pei G, Wong YH (2000). "Immunoglobulin G1 Fc fragment-tagged human opioid receptor-like receptor retains the ability to inhibit cAMP accumulation". Biological Signals and Receptors9 (5): 240–7. doi:10.1159/000014645. PMID10965058.
Ito E, Xie G, Maruyama K, Palmer PP (Dec 2000). "A core-promoter region functions bi-directionally for human opioid-receptor-like gene ORL1 and its 5'-adjacent gene GAIP". Journal of Molecular Biology304 (3): 259–70. doi:10.1006/jmbi.2000.4212. PMID11090272.
Okada K, Sujaku T, Chuman Y, Nakashima R, Nose T, Costa T, Yamada Y, Yokoyama M, Nagahisa A, Shimohigashi Y (Nov 2000). "Highly potent nociceptin analog containing the Arg-Lys triple repeat". Biochemical and Biophysical Research Communications278 (2): 493–8. doi:10.1006/bbrc.2000.3822. PMID11097863.
Serhan CN, Fierro IM, Chiang N, Pouliot M (Mar 2001). "Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4". Journal of Immunology166 (6): 3650–4. doi:10.4049/jimmunol.166.6.3650. PMID11238602.
Mandyam CD, Thakker DR, Christensen JL, Standifer KM (Aug 2002). "Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk". The Journal of Pharmacology and Experimental Therapeutics302 (2): 502–9. doi:10.1124/jpet.102.033159. PMID12130708.
Spampinato S, Di Toro R, Alessandri M, Murari G (Dec 2002). "Agonist-induced internalization and desensitization of the human nociceptin receptor expressed in CHO cells". Cellular and Molecular Life Sciences59 (12): 2172–83. doi:10.1007/s000180200016. PMID12568343.